Deep Origin in San Francisco, with a team comprised of Ginkgo Bioworks, Inc., ImmVue Therapeutics, Modeling Informed Design and Optimization, LLC, Netrias, LLC, Sanford Burnham Prebys Medical Discovery Institute, and Tessel Biosciences, Inc., intends to build an FDA-qualifiable, self-improving in silico ADME-Tox and dosage prediction platform aimed at reducing and eventually replacing animal models, so drug developers can test how a medicine moves through and affects the human body on a computer before it ever reaches a person.